Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05541003 · ClinicalTrials.gov registry record · Phase 2
Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT05541003 is a Phase 2 study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 12 participants.
The verdict
NCT05541003, a Phase 2 study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study aims to use a high-fiber supplementation, an intervention known to create shifts in the gut microbiota towards a healthier structure, to explore the relationship between gut microbiota, appetite control and feeding behavior in PWS patients.
Interventions
- DRUG NBT-NM108
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-01-06 |
| Est. Completion | 2023-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05541003
The ClinicalTrials.gov registry entry for NCT05541003 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NBT-NM108 is the first listed.
NCT05541003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05541003 about?
NCT05541003 is a clinical study titled "Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome". This study aims to use a high-fiber supplementation, an intervention known to create shifts in the gut microbiota towards a healthier structure, to explore the relationship between gut microbiota, appetite control and feeding behavior in PWS patients.
What is the current status of trial NCT05541003?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2023-01-06. Estimated completion is 2023-05-30.
What interventions are being tested in trial NCT05541003?
The interventions under investigation include: NBT-NM108 (DRUG).
Who is sponsoring clinical trial NCT05541003?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.